Drug intelligence / Profile preview

IK14800

Development stage: Preclinical
Lead developer: InterK Peptide Therapeutics
Modality: Peptides
Administration: Intraperitoneal

Overview

IK14800 is a synthetic immunomodulating peptide currently in preclinical development by InterK Peptide Therapeutics. It is designed to address skin cancer, particularly melanoma, and UV-induced skin DNA damage. The therapeutic candidate works by reducing DNA damage in the skin following ultraviolet irradiation and re-invigorating exhausted T cells to enhance the body's immune response against tumors. Preclinical studies have demonstrated its ability to suppress the growth of melanoma metastases, suggesting potential as both a protective and therapeutic agent in dermatological oncology.

Beyond the preview

Go deeper on IK14800.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IK14800.

Explore the full profile